Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12386402 | 0.92 | KDM4E (0.59) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL12386397 | 0.84 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL12622062 | 0.82 | L3MBTL1 (0.55) | KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12793323 | 0.82 | KDM4E (0.79) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL27839480 | 0.81 | USP2 (0.61) | POLBPKMALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5306415 | 0.81 | POLB (1.00) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL4009309 | 0.81 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2080837 | 0.81 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2831202 | 0.81 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL15231957 | 0.80 | POLB (0.67) | KDM4EPOLBALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008341-B2 | Central nervous system disorders; autoimmune diseases; anticancer agents; cardiovascular disorders; antiischemic agents; antiepileptic agents ; Alzheimer's disease; Huntington's disease; Parkinson's disease; spinal cord injuries; antiarthritic agents; transplant rejection; sepsis; brain disorders | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008341-B2 | Central nervous system disorders; autoimmune diseases; anticancer agents; cardiovascular disorders; antiischemic agents; antiepileptic agents ; Alzheimer's disease; Huntington's disease; Parkinson's disease; spinal cord injuries; antiarthritic agents; transplant rejection; sepsis; brain disorders | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1320526-B1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | MERCK SERONO SA (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255222-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255222-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-10-16 | — | — | US | disclosed |
| US-7417058-B2 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | LABORATOIRES SERONO S.A. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-7417058-B2 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | LABORATOIRES SERONO S.A. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-20040053917-A1 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1320526-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002026711-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053917-A1 | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | MAPK3, CBR3, MAPK1 | KDM4E 2172/4885POLB 4788/4885PKM 2512/4885 |
| US-20080255222-A1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | MAP3K5, MAP3K2, MAP3K21 | KDM4E 1305/4885POLB 3958/4885PKM 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.